Open AccessArylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan‐cancer
Author(s) -
Shen Yiming,
Wei Zhengyu,
Zhou Chongchang,
Song Jiangping,
Wang Jianing,
Wang Jiada,
Wu Linrong,
Fang Shenzhe,
Shen Zhisen
Publication year - 2022
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24600
Subject(s) - head and neck squamous cell carcinoma , sulfatase , biology , cancer research , cancer , medicine , oncology , biomarker , head and neck cancer , genetics , enzyme , biochemistry
Background Sulfatase gene family members mediate various biological functions in tumor stroma and tumor cell environments. However, the expressions and prognostic value of Arylsulfatase I ( ARSI ), a sulfatase gene family member, in head and neck squamous cell carcinoma (HNSC) have not been fully established. Methods Arylsulfatase I expressions in pan‐cancer were profiled using publicly available databases. Then, univariate Cox regression, Kaplan–Meier, and the Pearson's correlation analyses were performed to determine correlations between ARSI expressions and cancer prognosis, immune cell status, and drug sensitivity. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were used to assess the potential mechanisms underlying ARSI functions in HNSC. Results Arylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC. Elevated ARSI levels were associated with worse prognostic outcomes in HNSC patients. In addition, GSVA and GSEA showed that ARSI was highly involved in tumor cell escape and inflammatory responses. Expressions of ARSI negatively correlated with tumor mutation burden or microsatellite instability and positively correlated with immune‐related genes. Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939. Conclusion Arylsulfatase I is a promising prognostic and therapeutic target for HNSC.